Biogen (BIIB) Other Working Capital Changes (2009 - 2011)
Biogen (BIIB) posted quarterly Other Working Capital Changes of $54.0 million for Q2 2026, up 145.45% year-over-year from $22.0 million in Q2 2025, and down 39.33% quarter-over-quarter from $89.0 million in Q1 2026.
Biogen (BIIB) Other Working Capital Changes (2009 - 2011) Analysis & Trends
Biogen's Other Working Capital Changes history runs 16 years deep, the most recent figure standing at $54.0 million for Q2 2026.
- In Q2 2026, Other Working Capital Changes rose 145.45% year-over-year to $54.0 million; the TTM figure through Jun 2026 stood at $128.1 million (up 21250.0% YoY), while the FY2025 annual figure was $60.6 million, up 115.66% from the prior year.
- Other Working Capital Changes for Q2 2026 stood at $54.0 million, down from $89.0 million in the prior quarter.
- The five-year high for Other Working Capital Changes was $26.1 million in Q3 2010, with the low at -$17.1 million in Q2 2010.
- The 3-year median for Other Working Capital Changes is $6.4 million (2011), against an average of $2.8 million.
- The sharpest annual moves came in 2022 and 2025: Other Working Capital Changes slumped 1445.36% in 2022, then soared 379.89% in 2025.
- Biogen's Other Working Capital Changes stood at $34.9 million in 2022, then slumped by 291.4% to -$66.8 million in 2023, then jumped by 43.71% to -$37.6 million in 2024, then plunged by 217.29% to -$119.3 million in 2025, then surged by 145.26% to $54.0 million in 2026.
- Business Quant data shows BIIB's Other Working Capital Changes at $54.0 million in Q2 2026, $89.0 million in Q1 2026, and -$119.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.51 Bn | 632.75 Bn | 17.26 Bn |
| 2 | AbbVie | 470.18 Bn | 463.61 Bn | 12.70 Bn |
| 3 | Merck | 376.85 Bn | 369.71 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.42 Bn | 252.52 Bn | 12.86 Bn |
| 6 | Amgen | 236.70 Bn | 222.71 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 182.16 Bn | 178.98 Bn | 6.22 Bn |
| 8 | Pfizer | 159.30 Bn | 147.60 Bn | 10.94 Bn |
| 9 | Gsk | 106.12 Bn | 101.95 Bn | 8.24 Bn |
| 10 | Biogen | 32.07 Bn | 30.78 Bn | 1.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 12.13 Mn |
| Dec 31, 2011 | 12.13 Mn |
| Dec 31, 2011 | 12.13 Mn |
| Sep 30, 2011 | 761,000.00 |
| Sep 30, 2011 | 761,000.00 |
| Sep 30, 2011 | 761,000.00 |
| Jun 30, 2011 | 13.20 Mn |
| Jun 30, 2011 | 13.20 Mn |
| Jun 30, 2011 | 13.20 Mn |
| Mar 31, 2011 | 17.15 Mn |
| Mar 31, 2011 | 17.15 Mn |
| Mar 31, 2011 | 17.15 Mn |
| Dec 31, 2010 | -9.85 Mn |
| Dec 31, 2010 | -9.85 Mn |
| Dec 31, 2010 | -9.85 Mn |
| Sep 30, 2010 | 26.07 Mn |
| Sep 30, 2010 | 26.07 Mn |
| Sep 30, 2010 | 26.07 Mn |
| Jun 30, 2010 | -17.10 Mn |
| Jun 30, 2010 | -17.10 Mn |